CoChat

Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Bevacizumab (BEV, Avastin(®)) produces durable objective radiological responses of 20-26 %, median response durations of 16-18 weeks, and median overall survival (mOS) of 31-40 weeks. While the use of BEV is well-established, the lack of dose-response studies in glioblastoma (GBM) patients raises the question whether current dosing practice is optimal. As a result of differing approaches to BEV dosing that ranged from the FDA approved package insert dose of 10 mg/kg every 2 weeks to 7.5 mg/kg every 3-4 weeks, among physicians within Northern California Kaiser Permanente hospitals over 4+ years, we did an IRB-approved retrospective analysis of patients seen in Northern California Kaiser Permanente facilities and treated with BEV. Between September 1, 2008 and August 31, 2013, 181 patients received BEV for tumor progression/recurrence starting 2.6 weeks after completion of chemoradiation. The integrated BEV administered dose-week (AUCBEV) for all patients had a median AUCBEV of 3.6 mg·wk/kg). Maximum likelihood analysis found patients over 65 years did worse than younger patients (p = 0.004), women lived longer (p = 0.002), and patients treated below the AUCBEV did better than those treated above the median AUCBEV (p = 0.003). mOS for BEV starting 1 month after chemoradiation was 45 versus 68 weeks (p = 0.012) and BEV starting 3 months after chemoradiation was 40 versus 74 weeks (p = 0.0085). Dosing BEV at half the standard dose for progressive/recurrent GBM was at least equivalent to or, maybe better than standard dosing. Unexplained was the observation that females had longer OS with BEV than males.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11060-014-1693-x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Cited by

See all 67

Metadata

Authors
Levin, V. A., Mendelssohn, N. D., Chan, J., Stovall, M. C., Peak, S. J., Yee, J. L., Hui, R. L., & Chen, D. M.
Affiliations
Kaiser Permanente (US)
Corresponding author
Levin, Victor A.
Venue
Journal of Neuro-Oncology
Published
2015-01-11
Volume
122
Issue
1
Pages
145-150
ISSN
  • 0167-594X (ISSN-L)
  • 1573-7373
OpenAlex
W2013247986
Cited by
66
References
29
Citations by year
2026: 1 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 5 · 2015: 6
FWCI
5.22
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Neuro-Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
bevacizumab, glioblastoma, dose-response relationship, overall survival, dose reduction, recurrent glioblastoma, chemoradiotherapy, sex differences, age effects, anti-VEGF therapy
MeSH terms
Bevacizumab, Adult, Aged, Aged, 80 and over, Brain Neoplasms, Female, Follow-Up Studies, Glioblastoma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Salvage Therapy, Disease Progression, Angiogenesis Inhibitors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. https://app.cochat.ai/papers/10.1007/s11060-014-1693-x
The paper
Levin, V. A., Mendelssohn, N. D., Chan, J., Stovall, M. C., Peak, S. J., Yee, J. L., Hui, R. L., & Chen, D. M. (2015). Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-014-1693-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.